Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: A review on behalf of ECCO and EBMT

European Crohn's and Colitis Organisation (ECCO), European Society for Blood and Marrow Transplantation (EBMT), Autoimmune Diseases Working Party (ADWP), Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE)

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Despite the major recent progress in the treatment of Crohn's disease [CD], there is a subset of patients in whom the disease runs an aggressive course with progressive tissue damage requiring early and repeated surgical management. Increasing evidence supports sustained and profound improvement in gastrointestinal parameters and quality of life following high-dose immunosuppressive therapy and autologous haematopoietic stem cell transplantation [AHSCT] compared to standard therapy in this context. In addition, international transplant registry data reflect the use of AHSCT in CD outside of trials in selected patients. However, AHSCT may be associated with significant treatment-related complications with risk of transplant-related mortality. In a joint initiative, the European Crohn's and Colitis Organisation [ECCO] and the European Society for Blood and Marrow Transplantation [EBMT] have produced a state-of-the-art review of the rationale, evaluation, patient selection, stem cell mobilization and transplant procedures and long-term follow up. Given the unique spectrum of issues, we recommend that AHSCT should only be performed in experienced centres with expertise in both haematological and gastroenterological aspects of the procedure. Where possible, patients should be enrolled on clinical trials and data registered centrally. Future development should be coordinated at both national and international levels.

Original languageEnglish
Pages (from-to)476-488
Number of pages13
JournalJournal of Crohn's and Colitis
Volume12
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Hematopoietic Stem Cell Transplantation
Colitis
Crohn Disease
Transplantation
Bone Marrow
Organizations
Transplants
Hematopoietic Stem Cell Mobilization
Therapeutics
Immunosuppressive Agents
Patient Selection
Registries
Quality of Life
Clinical Trials
Mortality

Keywords

  • Autologous haematopoietic stem cell transplantation
  • Chemotherapy
  • Crohn's disease
  • Inflammatory bowel disease
  • Stem cells
  • Transplantation

ASJC Scopus subject areas

  • Gastroenterology

Cite this

European Crohn's and Colitis Organisation (ECCO), European Society for Blood and Marrow Transplantation (EBMT), Autoimmune Diseases Working Party (ADWP), & Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE) (2018). Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: A review on behalf of ECCO and EBMT. Journal of Crohn's and Colitis, 12(4), 476-488. https://doi.org/10.1093/ecco-jcc/jjx184

Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease : A review on behalf of ECCO and EBMT. / European Crohn's and Colitis Organisation (ECCO); European Society for Blood and Marrow Transplantation (EBMT); Autoimmune Diseases Working Party (ADWP); Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE).

In: Journal of Crohn's and Colitis, Vol. 12, No. 4, 01.04.2018, p. 476-488.

Research output: Contribution to journalReview article

European Crohn's and Colitis Organisation (ECCO), European Society for Blood and Marrow Transplantation (EBMT), Autoimmune Diseases Working Party (ADWP) & Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE) 2018, 'Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: A review on behalf of ECCO and EBMT', Journal of Crohn's and Colitis, vol. 12, no. 4, pp. 476-488. https://doi.org/10.1093/ecco-jcc/jjx184
European Crohn's and Colitis Organisation (ECCO), European Society for Blood and Marrow Transplantation (EBMT), Autoimmune Diseases Working Party (ADWP), Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE). Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: A review on behalf of ECCO and EBMT. Journal of Crohn's and Colitis. 2018 Apr 1;12(4):476-488. https://doi.org/10.1093/ecco-jcc/jjx184
European Crohn's and Colitis Organisation (ECCO) ; European Society for Blood and Marrow Transplantation (EBMT) ; Autoimmune Diseases Working Party (ADWP) ; Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE). / Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease : A review on behalf of ECCO and EBMT. In: Journal of Crohn's and Colitis. 2018 ; Vol. 12, No. 4. pp. 476-488.
@article{70c0e18e88a74c2080d70a6255a1bc2b,
title = "Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: A review on behalf of ECCO and EBMT",
abstract = "Despite the major recent progress in the treatment of Crohn's disease [CD], there is a subset of patients in whom the disease runs an aggressive course with progressive tissue damage requiring early and repeated surgical management. Increasing evidence supports sustained and profound improvement in gastrointestinal parameters and quality of life following high-dose immunosuppressive therapy and autologous haematopoietic stem cell transplantation [AHSCT] compared to standard therapy in this context. In addition, international transplant registry data reflect the use of AHSCT in CD outside of trials in selected patients. However, AHSCT may be associated with significant treatment-related complications with risk of transplant-related mortality. In a joint initiative, the European Crohn's and Colitis Organisation [ECCO] and the European Society for Blood and Marrow Transplantation [EBMT] have produced a state-of-the-art review of the rationale, evaluation, patient selection, stem cell mobilization and transplant procedures and long-term follow up. Given the unique spectrum of issues, we recommend that AHSCT should only be performed in experienced centres with expertise in both haematological and gastroenterological aspects of the procedure. Where possible, patients should be enrolled on clinical trials and data registered centrally. Future development should be coordinated at both national and international levels.",
keywords = "Autologous haematopoietic stem cell transplantation, Chemotherapy, Crohn's disease, Inflammatory bowel disease, Stem cells, Transplantation",
author = "{European Crohn's and Colitis Organisation (ECCO)} and {European Society for Blood and Marrow Transplantation (EBMT)} and {Autoimmune Diseases Working Party (ADWP)} and {Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE)} and Snowden, {John A.} and Juli{\'a}n Pan{\'e}s and Tobias Alexander and Matthieu Allez and Sandro Ardizzone and Daan Dierickx and J{\"u}rgen Finke and Peter Hasselblatt and Chris Hawkey and Majid Kazmi and Lindsay, {James O.} and Francesco Onida and Azucena Salas and Riccardo Saccardi and Severine Vermeire and Montserrat Rovira and Elena Ricart",
year = "2018",
month = "4",
day = "1",
doi = "10.1093/ecco-jcc/jjx184",
language = "English",
volume = "12",
pages = "476--488",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease

T2 - A review on behalf of ECCO and EBMT

AU - European Crohn's and Colitis Organisation (ECCO)

AU - European Society for Blood and Marrow Transplantation (EBMT)

AU - Autoimmune Diseases Working Party (ADWP)

AU - Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE)

AU - Snowden, John A.

AU - Panés, Julián

AU - Alexander, Tobias

AU - Allez, Matthieu

AU - Ardizzone, Sandro

AU - Dierickx, Daan

AU - Finke, Jürgen

AU - Hasselblatt, Peter

AU - Hawkey, Chris

AU - Kazmi, Majid

AU - Lindsay, James O.

AU - Onida, Francesco

AU - Salas, Azucena

AU - Saccardi, Riccardo

AU - Vermeire, Severine

AU - Rovira, Montserrat

AU - Ricart, Elena

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Despite the major recent progress in the treatment of Crohn's disease [CD], there is a subset of patients in whom the disease runs an aggressive course with progressive tissue damage requiring early and repeated surgical management. Increasing evidence supports sustained and profound improvement in gastrointestinal parameters and quality of life following high-dose immunosuppressive therapy and autologous haematopoietic stem cell transplantation [AHSCT] compared to standard therapy in this context. In addition, international transplant registry data reflect the use of AHSCT in CD outside of trials in selected patients. However, AHSCT may be associated with significant treatment-related complications with risk of transplant-related mortality. In a joint initiative, the European Crohn's and Colitis Organisation [ECCO] and the European Society for Blood and Marrow Transplantation [EBMT] have produced a state-of-the-art review of the rationale, evaluation, patient selection, stem cell mobilization and transplant procedures and long-term follow up. Given the unique spectrum of issues, we recommend that AHSCT should only be performed in experienced centres with expertise in both haematological and gastroenterological aspects of the procedure. Where possible, patients should be enrolled on clinical trials and data registered centrally. Future development should be coordinated at both national and international levels.

AB - Despite the major recent progress in the treatment of Crohn's disease [CD], there is a subset of patients in whom the disease runs an aggressive course with progressive tissue damage requiring early and repeated surgical management. Increasing evidence supports sustained and profound improvement in gastrointestinal parameters and quality of life following high-dose immunosuppressive therapy and autologous haematopoietic stem cell transplantation [AHSCT] compared to standard therapy in this context. In addition, international transplant registry data reflect the use of AHSCT in CD outside of trials in selected patients. However, AHSCT may be associated with significant treatment-related complications with risk of transplant-related mortality. In a joint initiative, the European Crohn's and Colitis Organisation [ECCO] and the European Society for Blood and Marrow Transplantation [EBMT] have produced a state-of-the-art review of the rationale, evaluation, patient selection, stem cell mobilization and transplant procedures and long-term follow up. Given the unique spectrum of issues, we recommend that AHSCT should only be performed in experienced centres with expertise in both haematological and gastroenterological aspects of the procedure. Where possible, patients should be enrolled on clinical trials and data registered centrally. Future development should be coordinated at both national and international levels.

KW - Autologous haematopoietic stem cell transplantation

KW - Chemotherapy

KW - Crohn's disease

KW - Inflammatory bowel disease

KW - Stem cells

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85044639355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044639355&partnerID=8YFLogxK

U2 - 10.1093/ecco-jcc/jjx184

DO - 10.1093/ecco-jcc/jjx184

M3 - Review article

AN - SCOPUS:85044639355

VL - 12

SP - 476

EP - 488

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 4

ER -